MANAGEMENT TEAM

Keith Dionne, Ph.D.
President and Chief Executive Officer

Dr. Dionne joined Surface Logix in October of 2008. He brings nearly 20 years of leadership experience in the biotechnology industry to the company. Prior to joining Surface Logix, Dr. Dionne was CEO of Alantos Pharmaceuticals, where he led the Company through its successful acquisition by Amgen for more than $300 million in cash. Prior to Alantos, Dr. Dionne held senior-level positions at Millennium Pharmaceuticals, including most recently Vice President of Research and Development Strategy and Vice President & General Manager: Technology Business. As Vice President of R&D Strategy, he chaired the Portfolio Development Committee responsible for advancing compounds from early development through launch. Dr. Dionne also led the Millennium/Aventis Technology Alliance, as well as the Millennium/Monsanto Agricultural Alliance, under which he spearheaded the start-up of Cereon, a wholly-owned subsidiary of Monsanto. Prior to that, Dr. Dionne was responsible for technology program management and strategic alliances. Before his tenure with Millennium, Dr. Dionne served as Head of Pre-Clinical Research & Development: Implants at ALZA Pharmaceuticals. While with ALZA, he led the development of the Duros™ family of implantable drug delivery systems and was responsible for guiding the development of Viadur™, a prostate cancer product, from concept to phase II clinical trials in less than three years. Dr. Dionne was one of four original scientists at CytoTherapeutics, Inc., a cell transplantation company. He has served as an Adjunct Professor in the Biomedical Department at Brown University. Dr. Dionne received both his Ph.D. in Chemical Engineering and his M.S. in the Program for Technology Policy from Massachusetts Institute of Technology.

 
Paul Sweetnam, Ph.D.
Chief Scientific Officer

Dr. Sweetnam joined Surface Logix in August of 2001. Prior to joining Surface Logix, Dr. Sweetnam was VP of Research Technologies at Bayer Pharmaceuticals. While at Bayer, Dr. Sweetnam's key focus areas were bioinformatics, genomics, protein biosciences, assay development, HTS, in-vivo and in-vitro pharmacokinetics, toxicology and comparative medicine. Dr. Sweetnam was also responsible for the identification, evaluation and integration of external opportunities in the areas of pharmacology, high throughput screening, molecular biology, protein biosciences and chemical diversity. During his tenure at Bayer, Dr. Sweetnam helped oversee the delivery of nine candidate molecules to development. Prior to joining Bayer, Dr. Sweetnam was employed by Pfizer Pharmaceuticals, where he developed and implemented the "Drug Pfinder" program, responsible for identifying, acquiring and optimizing potential and/or novel drug discovery targets. While at Novascreen, a division of Nova Pharmaceuticals, Dr. Sweetnam played an integral role in successfully implementing the first drug selectivity "Profiling" system for the Pharmaceutical Industry. Dr. Sweetnam is a graduate of the University of Maine, earned his Ph.D. in neurochemistry at Georgetown University, was a Postdoctoral Fellow in the Departments of Psychiatry and Pharmacology at Yale University School of Medicine, and was an assistant professor in the Department of Neurosurgery at the University Of Miami School Of Medicine.

 
Warwick Tong, MB ChB MPP
Senior Vice President, Development

Dr. Tong joined Surface Logix in August 2004. He brings over 12 years of pharmaceutical experience to Surface Logix. Prior to joining Surface Logix, Dr. Tong was a Vice President in World Wide Development at GlaxoSmithKline (GSK). Also at GSK, Dr. Tong held the positions of Vice President, Global Commercial Strategy for Anti-Infectives, Regional Business Development Director for Asia Pacific and Medical Director in New Zealand. In his commercial role at GSK, Dr. Tong was responsible for a franchise with annual global sales in excess of $3.2 billion and was responsible for launching two new anti-viral products. He has also led business development activities on a regional basis and in-licensing negotiations for a number of global assets at different stages of development. Dr. Tong is qualified as Senior Scholar in Medicine from Auckland University.

 
Winston Henderson
Vice President, General Counsel

Mr. Henderson joined Surface Logix in May 2000. Prior to joining Surface Logix, Mr. Henderson was an attorney with Kenyon & Kenyon. Prior to Kenyon & Kenyon, Mr. Henderson worked as a consultant for Accenture (formerly, Andersen Consulting). His experience covers many areas of intellectual property, including patent, trademark and copyright litigation, licensing and prosecution, corporate intellectual property strategy, valuation and due diligence. Mr. Henderson's patent litigation and prosecution experience is focused primarily in life sciences including biotechnology and medical-related devices. Mr. Henderson received both his B.S. in Biomedical & Electrical Engineering from Duke University and his J.D. from Duke University School of Law.

 
John Wm. Ferkany, Ph.D., M.A.S.
Vice President, Development

Dr. Ferkany joined Surface Logix in July 2005 as Vice President of Biology bringing over 20 years of experience from the biotechnology, biopharmaceutical and contract research management industries. Prior to joining Surface Logix, Dr. Ferkany served as Senior Vice President for Virtual Drug Development Incorporated, a privately held biotechnology company engaged in developing therapeutic strategies for biodefense. Dr. Ferkany has also served as Vice President and Chief Technical Officer of NovaScreen BioSciences Corporation, an international contract research organization providing screening, profiling and assay development services for pharmaceutical and biotechnology companies worldwide, and for government agencies including the National Institutes of Health. He also headed his own consulting firm focused on regulatory preclinical drug development. He also led the Central Nervous Research group at Nova Pharmaceutical Corporation, the first successful biotechnology spin-out from the Johns Hopkins University. Dr. Ferkany has a B.S. in Zoology from the University of Michigan, a doctoral degree in Biomedical Sciences from the University of Texas at Houston, and a Masters of Administrative Sciences awarded from the Johns Hopkins University in Baltimore.

 
Olivier Schueller, Ph.D.
Vice President, Chemical Development

Dr. Schueller joined Surface Logix in 1999 as one of its founding members. Dr. Schueller oversees scale-up and manufacture of active pharmaceutical ingredients and clinical trial materials and coordinates these activities with preclinical and clinical studies. Dr. Schueller received a Licence de Chimie from Université Pierre et Marie Curie (Paris VI), a Diplôme d’Ingénieur from Ecole Supérieure de Chimie Organique et Minérale (formerly located in Paris) and a Ph.D. in organic chemistry from Ohio State University. He was a postdoctoral fellow in the group of Prof. George Whitesides in the Department of Chemistry and Chemical Biology at Harvard University.

 
Bridget McCarthy Cole, Ph.D.
Vice President, Discovery

Dr. McCarthy joined Surface Logix in May 2006 as Vice President of Chemistry bringing over 10 years of pharmaceutical experience to the Company. Prior to joining Surface Logix, Dr. McCarthy held the position of Associate Director of Medicinal Chemistry at the Pfizer Research Technology Center in Cambridge, Ma. In this role Dr. McCarthy was responsible for managing medicinal and analytical chemistry in support of various drug discovery programs including targets in the areas of obesity, diabetes and inflammation. Prior to joining the Pfizer Cambridge site in 2001, Dr. McCarthy held the position of Project Leader in the Veterinary Medicine Research and Discovery Division in Groton, CT where she actively pursued the development of anti-obesity agents and was a key contributor to the discovery of Dirlotapide. Dr. McCarthy has a Ph.D. in organic chemistry from Brandeis University and conducted post-doctoral work in asymmetric catalysis at Boston College.
 

 
Enoch Kim, Ph.D.
Vice President, Research Technology

Dr. Kim joined Surface Logix in 1999 as one its founding members. Dr. Kim is responsible for the development and application of the Pharmacomer Technology Platform. In his most recent role as Director of Platform Application, he discovered SLx-4090, a gut-selective MTP inhibitor, currently in Phase 2 development. Dr. Kim received a B.A. from Hamilton College and a Ph.D. in physical organic chemistry from the Department of Chemistry at Harvard University under the guidance of Professor George Whitesides.